-
THE WILLINGNESS TO REIMBURSE: A SCOPING REVIEW OF APPROACHES TO GLOBAL HTA THRESHOLDS
Aug 11, 2026, 17:16 PM -
USING GENERATIVE AI WITH RETRIEVAL-AUGMENTED GENERATION TO AUTOMATE SLIDE DECK DEVELOPMENT FROM AMCP FORMULARY DOSSIERS
Aug 11, 2026, 17:16 PM -
EXTENDING THE VALIDATION OF ACCURACY FOR LARGE LANGUAGE MODEL (LLM)-/MACHINE LEARNING (ML)-EXTRACTED INFORMATION AND DATA (VALID) FRAMEWORK GLOBALLY: QUALITY ASSESSMENT OF LLM-DERIVED PROSTATE CANCER REAL-WORLD DATA IN THE UK
Aug 11, 2026, 17:16 PM -
THE POTENTIAL BURDEN OF ATTR-CM IN PORTUGAL: A GLOBAL AND PER FUNCTIONAL CLASS COST-OF-ILLNESS ANALYSIS
Aug 11, 2026, 17:16 PM -
THE IMPACT OF GERMANY'S 2008 NATIONWIDE SKIN CANCER SCREENING PROGRAM ON AGE-STANDARDIZED MELANOMA MORTALITY: AN UPDATE USING SYNTHETIC CONTROL METHODS
Aug 11, 2026, 17:16 PM -
HEALTHCARE RESOURCE UTILIZATION (HCRU) AND ASSOCIATED COSTS IN PATIENTS WITH STAGE III MERKEL CELL CARCINOMA (MCC) TREATED WITH FIRST-LINE (1L) AVELUMAB IN A REAL-WORLD SETTING: RESULTS FROM THE MCC-TRIM REGISTRY
Aug 11, 2026, 17:16 PM -
EFFICACY AND SAFETY OF PALOPEGTERIPARATIDE IN CHRONIC HYPOPARATHYROIDISM - A SYSTEMATIC LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
FACTUAL OR EVALUATIVE? HOW THE LANGUAGE OF JOINT CLINICAL ASSESSMENT REPORTS SHAPES NATIONAL APPRAISAL
Aug 11, 2026, 17:16 PM -
HOSPITAL CAPACITY USE IN DIFFUSE LARGE B-CELL LYMPHOMA CARE: A POPULATION-BASED TREATMENT-PATHWAY MODEL
Aug 11, 2026, 17:16 PM -
TRENDS IN GLP-1 RECEPTOR AGONIST UTILIZATION, EXPENDITURE, OUT-OF-POCKET BURDEN, AND FINANCIAL TOXICITY AMONG US ADULTS, 2017-2023
Aug 11, 2026, 17:16 PM -
ESTIMATING THE HEALTH IMPACT OF INTENSIFYING LIPID-LOWERING THERAPY IN PATIENTS AT RISK FOR OR DIAGNOSED WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN DENMARK
Aug 11, 2026, 17:16 PM -
EPIDEMIOLOGY, DISEASE MANAGEMENT, QUALITY OF LIFE, AND ECONOMIC BURDEN OF NON-SEGMENTAL VITILIGO IN FRANCE: A SYSTEMATIC LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
ASSOCIATIONS BETWEEN HEALTHCARE RESOURCE USE AND TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)
Aug 11, 2026, 17:16 PM -
TREATMENT SEQUENCING MODELS IN ONCOLOGY; KEY CONSIDERATIONS WHEN COMBINING TRIAL DATA AND EXTERNAL EVIDENCE
Aug 11, 2026, 17:16 PM -
REAL-WORLD TREATMENT PATTERNS AMONG PATIENTS WITH FOLLICULAR LYMPHOMA IN KOREA: COMPARISONS BY POD24 STATUS USING NATIONWIDE CLAIMS DATA
Aug 11, 2026, 17:16 PM -
COST AND HCRU CONSEQUENCES OF SWITCHING FROM EXISTING LONG-TERM PROPHYLAXIS TO DONIDALORSEN IN HEREDITARY ANGIOEDEMA
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF OBINUTUZUMAB FOR THE TREATMENT OF ACTIVE LUPUS NEPHRITIS IN COLOMBIA: FROM HEALTHCARE SYSTEM AND SOCIETAL PERSPECTIVES
Aug 11, 2026, 17:16 PM -
ESTIMATING THE RETURN ON PATIENT ENGAGEMENT IN CLINICAL TRIALS: EVIDENCE FROM A RISK-ADJUSTED NET PRESENT VALUE MODEL FOR A SOLID TUMOR ONCOLOGY PRODUCT
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF FIRST-LINE NIVOLUMAB-BASED THERAPY FOR HER2-NEGATIVE ADVANCED GASTRIC CANCER, GASTROESOPHAGEAL JUNCTION CANCER, AND ESOPHAGEAL ADENOCARCINOMA IN JAPAN
Aug 11, 2026, 17:16 PM -
WE-ACCESS-CLL SURVEY - REIMBURSEMENT AND ACCESS TO NOVEL FIRST-LINE TREATMENTS FOR CHRONIC LYMPHOCYTIC LEUKEMIA IN POLAND AND WESTERN EUROPE
Aug 11, 2026, 17:16 PM
